JP2016536012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536012A5 JP2016536012A5 JP2016549206A JP2016549206A JP2016536012A5 JP 2016536012 A5 JP2016536012 A5 JP 2016536012A5 JP 2016549206 A JP2016549206 A JP 2016549206A JP 2016549206 A JP2016549206 A JP 2016549206A JP 2016536012 A5 JP2016536012 A5 JP 2016536012A5
- Authority
- JP
- Japan
- Prior art keywords
- pkal
- inhibitor
- assay
- subject
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361893505P | 2013-10-21 | 2013-10-21 | |
| US61/893,505 | 2013-10-21 | ||
| US201461939837P | 2014-02-14 | 2014-02-14 | |
| US61/939,837 | 2014-02-14 | ||
| PCT/US2014/061247 WO2015061183A1 (en) | 2013-10-21 | 2014-10-17 | Assays for determining plasma kallikrein system biomarkers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144118A Division JP7135039B2 (ja) | 2013-10-21 | 2020-08-28 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016536012A JP2016536012A (ja) | 2016-11-24 |
| JP2016536012A5 true JP2016536012A5 (2) | 2017-11-24 |
| JP6757252B2 JP6757252B2 (ja) | 2020-09-16 |
Family
ID=52993413
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549206A Active JP6757252B2 (ja) | 2013-10-21 | 2014-10-17 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2020144118A Active JP7135039B2 (ja) | 2013-10-21 | 2020-08-28 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2022137393A Active JP7668772B2 (ja) | 2013-10-21 | 2022-08-31 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2024117419A Pending JP2024150637A (ja) | 2013-10-21 | 2024-07-23 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144118A Active JP7135039B2 (ja) | 2013-10-21 | 2020-08-28 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2022137393A Active JP7668772B2 (ja) | 2013-10-21 | 2022-08-31 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2024117419A Pending JP2024150637A (ja) | 2013-10-21 | 2024-07-23 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11372002B2 (2) |
| EP (2) | EP3060582B1 (2) |
| JP (4) | JP6757252B2 (2) |
| KR (4) | KR20230054745A (2) |
| CN (1) | CN105873951A (2) |
| AU (3) | AU2014340450B2 (2) |
| BR (1) | BR112016008970B1 (2) |
| CA (1) | CA2927824C (2) |
| DK (1) | DK3060582T3 (2) |
| ES (1) | ES2837858T3 (2) |
| IL (3) | IL289514B2 (2) |
| PL (1) | PL3060582T3 (2) |
| WO (1) | WO2015061183A1 (2) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201800552T1 (it) | 2010-01-06 | 2018-11-09 | Dyax Corp | Proteine che legano la callicreina plasmatica |
| KR102320178B1 (ko) * | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| EP4234583A3 (en) * | 2013-01-20 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| CA2927695C (en) | 2013-10-21 | 2022-03-01 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
| WO2015061183A1 (en) | 2013-10-21 | 2015-04-30 | Dyax Corp. | Assays for determining plasma kallikrein system biomarkers |
| EA038532B1 (ru) | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| KR102607829B1 (ko) * | 2015-03-30 | 2023-12-01 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도 |
| JP6907188B2 (ja) | 2015-08-13 | 2021-07-21 | ダイアックス コーポレーション | 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管 |
| EP4354146B1 (en) | 2015-10-19 | 2026-04-15 | Takeda Pharmaceutical Company Limited | Immunoassay for the detection of cleaved high molecular weight kininogen |
| KR102874711B1 (ko) * | 2015-12-15 | 2025-10-23 | 다케다 파머수티컬 컴패니 리미티드 | 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법 |
| US11340237B2 (en) * | 2016-09-16 | 2022-05-24 | Takeda Pharmaceutical Company Limited | Metabolite biomarkers for diseases associated with the contact activation system |
| IL265195B2 (en) * | 2016-09-16 | 2025-02-01 | Dyax Corp | Protein biomarkers for diseases related to the activation system |
| EA201990730A1 (ru) | 2016-09-16 | 2019-08-30 | Дайэкс Корп. | Рнк-биомаркеры для наследственного ангионевротического отека |
| EP3521828A1 (en) * | 2018-01-31 | 2019-08-07 | Centogene AG | Method for the diagnosis of hereditary angioedema |
| WO2019165308A1 (en) * | 2018-02-22 | 2019-08-29 | The Regents Of The University Of California | Threshold-stimulated plasma kallikrein activity as a biomarker for diagnosis of bradykinin-mediated angioedema |
| CN111057745B (zh) * | 2019-12-30 | 2022-08-12 | 中国科学院生态环境研究中心 | 一种物质的血液毒性效应的高通量筛选方法 |
| EP4090427A1 (en) | 2020-01-13 | 2022-11-23 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| US20230174674A1 (en) * | 2020-04-04 | 2023-06-08 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome |
| CN113777331A (zh) * | 2020-06-09 | 2021-12-10 | 张曼 | 尿液激肽原-1及其多肽片段在烧伤中的应用 |
| CN114166924B (zh) * | 2021-12-03 | 2024-11-22 | 中国医学科学院北京协和医院 | 尿液蛋白标志物在诊断遗传性血管水肿中的用途 |
| EP4548103A2 (en) * | 2022-06-30 | 2025-05-07 | Takeda Pharmaceutical Company Limited | Protein biomarkers for lanadelumab treatment |
| WO2025153806A1 (en) * | 2024-01-15 | 2025-07-24 | Kalvista Pharmaceuticals Limited | Methods for determining amidolytic activity |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1312564C (en) | 1985-07-12 | 1993-01-12 | Robert W. Colman | Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same |
| US5047323A (en) | 1986-01-22 | 1991-09-10 | Temple University Of The Commonwealth System Of Higher Education | Method for detecting human kininogen using monoclonal antibodies thereto |
| US4908431A (en) | 1986-01-22 | 1990-03-13 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human kininogen and methods of preparing same |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPS63185398A (ja) * | 1986-09-10 | 1988-07-30 | Nippon Zoki Pharmaceut Co Ltd | 生理活性物質測定法 |
| US4882272A (en) | 1986-10-01 | 1989-11-21 | Temple University - Of The Commonwealth System Of Higher Education | High molecular weight kininogen assay |
| US5025796A (en) | 1988-12-01 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1993003748A1 (en) | 1991-08-13 | 1993-03-04 | Temple University - Of The Commonwealth System Of Higher Education | Modulation of blood pressure and inhibition of platelet activation with kininogen fragment |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| WO1995021601A2 (en) | 1994-01-11 | 1995-08-17 | Protein Engineering Corporation | Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof |
| JPH1084995A (ja) | 1996-09-12 | 1998-04-07 | Nippon Zoki Pharmaceut Co Ltd | 血液凝固第ｘｉｉ因子活性化法 |
| US5789261A (en) | 1996-10-30 | 1998-08-04 | Temple University Of The Commonwealth System Of Higher Education | Solid phase immunoassay |
| US6242210B1 (en) | 1997-05-20 | 2001-06-05 | Actinova Limited | Treatment of bacterial infections |
| JP4346798B2 (ja) | 1999-08-19 | 2009-10-21 | 協和メデックス株式会社 | Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。 |
| US6994852B1 (en) | 1999-11-12 | 2006-02-07 | Temple University-Of The Commonwealth System Of Higher Education | Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
| US7067713B2 (en) | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| US7678541B2 (en) | 2000-11-21 | 2010-03-16 | Hologic, Inc. | Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction |
| JP2002221519A (ja) | 2001-01-29 | 2002-08-09 | Sysmex Corp | 抗凝固剤およびそれを用いた抗凝固剤処理方法 |
| US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
| US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| ES2348230T3 (es) | 2002-06-07 | 2010-12-01 | Dyax Corp. | Prevención y reducción de la isquemia. |
| WO2004005934A2 (en) | 2002-07-04 | 2004-01-15 | Oxford Glycosciences (Uk) Ltd | Toxicity markers |
| US20070003552A1 (en) | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
| EP1598428A1 (en) * | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| CA2575791A1 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| PL1981519T3 (pl) | 2005-12-29 | 2018-07-31 | Dyax Corp. | Hamowanie proteaz |
| US7276480B1 (en) | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
| WO2008016883A2 (en) | 2006-07-31 | 2008-02-07 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| JP2010510528A (ja) | 2006-11-22 | 2010-04-02 | ライフ テクノロジーズ コーポレーション | 自己免疫疾患のバイオマーカー |
| US20090075887A1 (en) | 2007-08-21 | 2009-03-19 | Genzyme Corporation | Treatment with Kallikrein Inhibitors |
| US8263347B2 (en) | 2007-10-18 | 2012-09-11 | Miyazaki Prefectural Industrial Support Foundation | Biomarker for diagnosis of liver disease |
| AU2008315938B2 (en) * | 2007-10-22 | 2014-11-27 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
| CA2729937A1 (en) | 2008-07-07 | 2010-01-14 | Nippon Zoki Pharmaceutical Co., Ltd. | Fibromyalgia test method |
| JP2012507723A (ja) | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
| EP2369930A4 (en) | 2008-12-02 | 2012-10-03 | Joslin Diabetes Ct | METHOD OF REDUCING BLOOD PRESSURE USING PLASMATIC KALLICREIN INHIBITORS |
| US8637454B2 (en) | 2009-01-06 | 2014-01-28 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| FR2942233B1 (fr) | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre |
| KR101077275B1 (ko) | 2009-05-07 | 2011-10-27 | 한국기초과학지원연구원 | 당단백질의 당쇄화를 이용한 암 진단 방법 |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| AU2010330743A1 (en) | 2009-12-18 | 2012-07-05 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| US9206123B2 (en) | 2009-12-18 | 2015-12-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| SMT201800552T1 (it) | 2010-01-06 | 2018-11-09 | Dyax Corp | Proteine che legano la callicreina plasmatica |
| WO2012009447A2 (en) | 2010-07-13 | 2012-01-19 | University Of Rochester | THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
| EP2645932B1 (en) | 2010-12-02 | 2016-03-02 | Becton, Dickinson and Company | Blood collection devices containing blood stabilization agent |
| KR102320178B1 (ko) * | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| EP3320922A1 (en) * | 2011-06-10 | 2018-05-16 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (klkb1) expression |
| WO2012170947A2 (en) | 2011-06-10 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| FR2983215B1 (fr) * | 2011-11-28 | 2013-12-20 | Univ Grenoble 1 | Dosage de la capacite de controle de c1inh |
| EP4234583A3 (en) | 2013-01-20 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| RU2015136025A (ru) | 2013-02-01 | 2017-03-06 | Бектон, Дикинсон энд Кампани | Устройства для сбора крови, содержащие добавки, ингибирующие контактный путь свертывания крови |
| WO2015061183A1 (en) | 2013-10-21 | 2015-04-30 | Dyax Corp. | Assays for determining plasma kallikrein system biomarkers |
| CA2927695C (en) | 2013-10-21 | 2022-03-01 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
| EA038532B1 (ru) | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| EP4354146B1 (en) | 2015-10-19 | 2026-04-15 | Takeda Pharmaceutical Company Limited | Immunoassay for the detection of cleaved high molecular weight kininogen |
| KR102874711B1 (ko) | 2015-12-15 | 2025-10-23 | 다케다 파머수티컬 컴패니 리미티드 | 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법 |
| EP4096687A4 (en) | 2020-01-28 | 2024-02-28 | Orgenesis Inc. | Process and system for acellular therapy |
-
2014
- 2014-10-17 WO PCT/US2014/061247 patent/WO2015061183A1/en not_active Ceased
- 2014-10-17 ES ES14856778T patent/ES2837858T3/es active Active
- 2014-10-17 CN CN201480070281.6A patent/CN105873951A/zh active Pending
- 2014-10-17 KR KR1020237012295A patent/KR20230054745A/ko not_active Ceased
- 2014-10-17 BR BR112016008970-7A patent/BR112016008970B1/pt active IP Right Grant
- 2014-10-17 KR KR1020227027698A patent/KR102521947B1/ko active Active
- 2014-10-17 EP EP14856778.7A patent/EP3060582B1/en active Active
- 2014-10-17 IL IL289514A patent/IL289514B2/en unknown
- 2014-10-17 CA CA2927824A patent/CA2927824C/en active Active
- 2014-10-17 PL PL14856778T patent/PL3060582T3/pl unknown
- 2014-10-17 EP EP20197583.6A patent/EP3808857B1/en active Active
- 2014-10-17 JP JP2016549206A patent/JP6757252B2/ja active Active
- 2014-10-17 KR KR1020257014548A patent/KR20250066486A/ko active Pending
- 2014-10-17 DK DK14856778.7T patent/DK3060582T3/da active
- 2014-10-17 US US15/030,811 patent/US11372002B2/en active Active
- 2014-10-17 KR KR1020167013432A patent/KR102432826B1/ko active Active
- 2014-10-17 AU AU2014340450A patent/AU2014340450B2/en active Active
-
2016
- 2016-04-19 IL IL245205A patent/IL245205B/en active IP Right Grant
-
2020
- 2020-04-19 IL IL274055A patent/IL274055B/en unknown
- 2020-08-10 AU AU2020217316A patent/AU2020217316B2/en active Active
- 2020-08-28 JP JP2020144118A patent/JP7135039B2/ja active Active
-
2021
- 2021-12-20 US US17/555,636 patent/US12442824B2/en active Active
-
2022
- 2022-08-31 JP JP2022137393A patent/JP7668772B2/ja active Active
-
2024
- 2024-05-21 AU AU2024203355A patent/AU2024203355A1/en active Pending
- 2024-07-23 JP JP2024117419A patent/JP2024150637A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016536012A5 (2) | ||
| Pan et al. | No evidence of severe acute respiratory syndrome–coronavirus 2 in semen of males recovering from coronavirus disease 2019 | |
| Ma et al. | Single-cell transcriptomic atlas of primate cardiopulmonary aging | |
| Ouyang et al. | Dysregulated serum MiRNA profile and promising biomarkers in dengue-infected patients | |
| Huang et al. | Urinary Xist is a potential biomarker for membranous nephropathy | |
| Hamaguchi et al. | Origin of circulating free DNA in sepsis: analysis of the CLP mouse model | |
| Ye et al. | The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma | |
| JP2016511823A5 (2) | ||
| Li et al. | MiR-217 is involved in the carcinogenesis of gastric cancer by down-regulating CDH1 expression | |
| MX2020001156A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| JP2017500584A5 (2) | ||
| Kovalenko et al. | ROS production, intracellular HSP70 levels and their relationship in human neutrophils: effects of age | |
| BR112016019740A2 (pt) | monitoramento do estado de inflamação | |
| JP2008537474A5 (2) | ||
| JP2015523569A5 (2) | ||
| JP7463351B2 (ja) | 脳卒中の血液バイオマーカー | |
| CN106544342B (zh) | Mt2a基因组蛋白乙酰化修饰检测试剂盒及引物对 | |
| US20190383809A1 (en) | A Novel Autophagy-Related Nourin Gene-Based RNA Network as Early Biomarkers for Cardiac Patients | |
| Ehrnhoefer et al. | Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons | |
| Zhai et al. | Value of blood-based microRNAs in the diagnosis of acute myocardial infarction: a systematic review and meta-analysis | |
| Solheim et al. | Prothrombotic markers in patients with acute myocardial infarction and left ventricular thrombus formation treated with pci and dual antiplatelet therapy | |
| MX2016006782A (es) | Un metodo para predecir la capacidad de respuesta a un tratamiento con un inhibidor del egfr. | |
| RU2014124032A (ru) | Однонуклеотидный полиморфизм на хромосоме 15, который позволяет прогнозировать восприимчивость к лечению вируса гепатита с | |
| Shen et al. | Screening of differentially expressed genes related to severe sepsis induced by multiple trauma with DNA microarray. | |
| WO2015121737A4 (en) | Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure |